The Absolute Effect / Evidence index
Neoadjuvant · Phase III open-label three-arm randomized; N=601 locally advanced oesophageal SCC. Neoadjuvant CF vs DCF vs CF+RT. Primary endpoint OS. · 3-year OS: DCF 72.1% vs CF 62.6% (HR 0.68
JCOG1109 NExT
Clinical question: Does neoadjuvant DCF or CF plus radiotherapy improve OS over CF in locally advanced oesophageal squamous cell carcinoma?
3-year OS: DCF 72.1% vs CF 62.6% (HR 0.68; P=0.006); CF+RT 68.3% (HR 0.84; P=0.12). Later 5-year OS: 65.1%, 51.9%, 60.2%, respectively. · Registry:
Design, population and treatment
Phase III open-label three-arm randomized; N=601 locally advanced oesophageal SCC. Neoadjuvant CF vs DCF vs CF+RT. Primary endpoint OS.
Key efficacy outcome
Toxicity and surgical complications differ by regimen; full primary tables required for detailed comparative rates.
Safety and absolute effect
3-year OS (%)
https://pubmed.ncbi.nlm.nih.gov/38876133/
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.